2018SASL专家观点声明_慢性丙型肝炎的治疗（更新版）.pdf

Treatment of Chronic Hepatitis C - August 2018 Update SASL-SSI Expert Opinion Statement Written by: Darius Moradpour, Jan Fehr, David Semela, Andri Rauch, Beat Müllhaupt Reviewed and approved by: Philip Bruggmann, Andreas Cerny, Nicolas Goossens, Andrea De Gottardi, Markus H. Heim, Beat Helbling, Valérie McLin, Francesco Negro, Laura Rubbia-Brandt and Christian Toso for SASL as well as Hansjakob Furrer, Claude Scheidegger and Pietro Vernazza for SSI. Introduction This document represents an update of the last version of the Swiss Association for the Study of the Liver (SASL) and Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement (EOS) on the Treatment of Chronic Hepatitis C published in November 2017 (www.sasl.ch; www.sggssg.ch, www.sginf.ch). Recommendations are based on the results of phase 3 or selected phase 2 clinical studies (1-10), the European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C (www.easl.eu) (11) and the Recommendations by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) (). The reader is referred to these documents as well as the Fachinformation approved by Swissmedic (pendium.ch or www.swissmedicinfo.ch) and the Spezialitätenliste of the Swiss Federal Office of Public Health (FOPH) (www.spezialitaetenliste.ch) for further information, including key references and sustained virologic response (SVR) rates that can be expected with the different treatment regimens